Company Overview
Snapshot
Founded in November 2010 by Yanay Ofran, Prof. and Avi Molcho, Biolojic Design operates with 51–200 employees. The company has secured funding across three rounds from four investors. In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, potentially valued at up to 346 million euros.
Business overview
Biolojic Design is a biopharmaceutical company focused on developing human antibody-based therapeutics for cancer and other diseases. The company utilizes proprietary algorithms and computational tools to re-engineer antibodies, enabling them to bind new epitopes. This re-epitoping technology allows for the creation of functional antibodies for challenging targets. Biolojic Design serves the pharmaceutical and biotechnology industries, operating within the Health Tech & Life Sciences sector, specifically in drug discovery and development.
Strategic signal
Biolojic Design's drug discovery collaboration with Merck, announced in June 2024 and potentially worth up to 346 million euros, signals strong validation of its computational antibody design platform. This partnership demonstrates significant commercial interest in their re-epitoping technology and positions the company for substantial growth in the biopharmaceutical market, attracting further investor and industry attention.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent collaboration for Biolojic Design?
- In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, which has a potential value of up to 346 million euros.
- Which company acquired rights to Biolojic Design's asthma treatment?
- In December 2023, Teva acquired the rights for Biolojic Design's asthma treatment.
- When did Biolojic Design appoint its Chief Scientific Officer?
- Biolojic Design appointed Ronald Herbst, Ph.D., as Chief Scientific Officer in September 2022.
- What was the nature of the collaboration between Biolojic Design and Lilly?
- In March 2021, Lilly and Biolojic Design announced a research collaboration to discover and develop antibody therapies for diabetes.